ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1818

Distribution and Morphological Changes of Adventitial Fibroblasts in Healthy and Scleroderma Skin

Banafsheh Nazari1, Tracy Tabib2, Christina Morse3 and Robert Lafyatis2, 1UPMC-Mercy, Pittsburgh, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh

Meeting: ACR Convergence 2024

Keywords: Fibroblasts, Dermal, Scleroderma

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Our previous single-cell RNA-sequencing study identified two major fibroblast subpopulations in healthy skin biopsies: SFRP2/DPP4 and FMO1/LSP1 fibroblasts¹. Additionally, we discovered that adventitial fibroblasts are comprised of two primary clusters based on APOE expression levels: APOE^hi/CCL19/C7-expressing fibroblasts and APOE^low/FMO1/MYOC-expressing fibroblasts. We showed that FMO1/MYOC-expressing fibroblasts exhibit both perivascular and interstitial distribution, whereas CCL19-secreting fibroblasts are predominantly perivascular2. Although different studies suggest the importance of vascular injury in the pathophysiology of scleroderma (SSc), modifications in adventitial fibroblasts and their morphological changes remain poorly understood. Here, we aim to study the changes in the distribution patterns of adventitial fibroblasts in healthy skin samples compared to SSc skin biopsies.

Methods: Forearm skin biopsies were obtained from 12 healthy individuals and 8 scleroderma patients following an approved protocol by the Institutional Review Board of the University of Pittsburgh School of Medicine. Paraffin-embedded skin samples were used for double and triple immunofluorescence staining, using Tyramide amplification and various antibodies targeting adventitial fibroblast markers such as CCL19, MYOC, and FMO1. Confocal microscopy was performed using Olympus FluoView 3000.

Results: Our analysis revealed dramatic changes in the distribution of adventitial fibroblasts between healthy and SSc skin samples. In healthy skin, CCL19 and MYOC stained overlapping populations of adventitial fibroblasts. In SSc skin, we observed a marked increase in CCL19-expressing fibroblasts, predominantly around the vasculature with extensions into the interstitium adjacent to vascular structures. These cells appeared to be denser in the upper dermis, particularly the papillary dermis. In patients with advanced SSc, this expansion into interstitium was more pronounced, while in healthy individuals the distribution pattern of CCL19 fibroblasts remained limited to the perivascular regions. Similarly, FMO1 and MYOC-expressing fibroblasts exhibited expanded interstitial presence in SSc skin, following the pattern observed in CCL19 expansion. Interestingly, MYOC-positive cells also showed increased presence in the papillary dermis of SSc skin, mirroring the distribution of CCL19 fibroblasts.

Conclusion: Our study indicates complex patterns of adventitial fibroblasts, expressing overlapping markers. These fibroblast populations appear to infiltrate the interstitium in the skin of SSc patients compared to healthy samples. These differences along with the increase in specific fibroblast subpopulations suggest that changes in adventitial fibroblasts may have a critical role in modifying vascular integrity and perivascular inflammation. These studies using protein markers confirm and extend our previous observations, characterizing various adventitial subpopulations by single-cell RNA sequencing. Future studies using spatial transcriptomics will provide further insights into the role of changes in different fibroblast subpopulations in SSc skin.

Supporting image 1

Figure 1: Immunofluorescent Staining of CCL19-MYOC Positive Adventitial Fibroblasts in Normal Skin, 60x

Supporting image 2

Figure 2: Immunofluorescent Staining of CCL19-MYOC-SMA Positive Adventitial Fibroblasts in Scleroderma Skin, 60x

Supporting image 3

Figure 3: Immunofluorescent Staining of CCL19-FMO1-SMA Positive Adventitial Fibroblasts in Scleroderma Skin, 60x


Disclosures: B. Nazari: None; T. Tabib: None; C. Morse: None; R. Lafyatis: None.

To cite this abstract in AMA style:

Nazari B, Tabib T, Morse C, Lafyatis R. Distribution and Morphological Changes of Adventitial Fibroblasts in Healthy and Scleroderma Skin [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/distribution-and-morphological-changes-of-adventitial-fibroblasts-in-healthy-and-scleroderma-skin/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distribution-and-morphological-changes-of-adventitial-fibroblasts-in-healthy-and-scleroderma-skin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology